H.C. Wainwright Boosts Price Target for Structure Therapeutics (GPCR) | GPCR Stock News

Author's Avatar
May 12, 2025

H.C. Wainwright has increased its price target for Structure Therapeutics (GPCR, Financial) from $75 to $80, while maintaining a Buy rating on the stock. The firm highlights the unique structural attributes of aleniglipron, noting that these could lead to distinctive weight-loss results in the ACCESS trials. Additionally, the data regarding orforglipron and danuglipron appears optimistic for the future of aleniglipron.

Wall Street Analysts Forecast

1921900122338390016.png

Based on the one-year price targets offered by 14 analysts, the average target price for Structure Therapeutics Inc (GPCR, Financial) is $79.00 with a high estimate of $120.00 and a low estimate of $50.00. The average target implies an upside of 208.96% from the current price of $25.57. More detailed estimate data can be found on the Structure Therapeutics Inc (GPCR) Forecast page.

Based on the consensus recommendation from 14 brokerage firms, Structure Therapeutics Inc's (GPCR, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.